Subsequent Events

3 Months Ended

Mar. 31, 2025

Subsequent Events [Abstract]

Subsequent Events

Subsequent Events

On April 29, 2025, the Company announced a strategic plan designed to focus the Company’s resources on its expanding portfolio of clinical candidates in Duchenne muscular dystrophy (“DMD”) and key preclinical programs. Effective May 2, 2025, the new strategic plan will include enhanced hiring efforts to support planned global clinical trial execution in DMD, as well as focused workforce reductions in select research areas, which are expected to reduce the Company’s workforce by approximately 20%. The Company is prioritizing the acceleration of its DMD clinical candidates (ENTR-601-44, -45, -50, and -51), ocular programs and maturing platform investments. In connection with the new strategic plan, the Company expects to incur aggregate charges of approximately $2 million in total expenses related to the reduction in force, consisting primarily of one-time severance payments and continued healthcare benefits for a specific period of time. The costs are expected to be primarily incurred in the second quarter of 2025. The Company may also incur other charges or cash expenditures not currently contemplated or that cannot be currently estimated due to events that may occur as a result of, or be associated with, the new strategic plan and related workforce reduction. The workforce reduction is expected to be substantially completed by the end of the second quarter of 2025.